Curative Biotechnology Inc
OTC:CUBT
Net Margin
Curative Biotechnology Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
US |
C
|
Curative Biotechnology Inc
OTC:CUBT
|
9.2m USD | N/A | |
UK |
E
|
Eight Capital Partners PLC
F:ECS
|
633.6T EUR | N/A | |
US |
G
|
GE Vernova LLC
NYSE:GEV
|
132.9B USD |
5%
|
|
US |
C
|
China Industrial Group Inc
OTC:CIND
|
91.7B USD |
9%
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
81.5B Zac |
69%
|
|
US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
80B USD |
-44%
|
|
US |
C
|
Circle Internet Group Inc
NYSE:CRCL
|
53B USD | N/A | |
US |
![]() |
Coupang Inc
F:788
|
44.3B EUR |
1%
|
|
ID |
![]() |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
553T IDR |
18%
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
26.6B CHF |
5%
|
|
US |
R
|
Reddit Inc
NYSE:RDDT
|
25.6B USD |
8%
|
Curative Biotechnology Inc
Glance View
Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The firm's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a immune therapy to treat rabies. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation to treat degenerative eye disease.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Curative Biotechnology Inc's most recent financial statements, the company has Net Margin of 0%.